Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.
The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described.
Brown
Matthew F
MF
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. matthew.f.brown@pfizer.com
Bahnck
Kevin B
KB
Blumberg
Laura C
LC
Brissette
William H
WH
Burrell
Sara A
SA
Driscoll
James P
JP
Fedeles
Flavia
F
Fisher
Michael B
MB
Foti
Robert S
RS
Gladue
Ronald P
RP
Guzman-Martinez
Aikomari
A
Hayward
Matthew M
MM
Lira
Paul D
PD
Lillie
Brett M
BM
Lu
Yi
Y
Lundquist
Greg D
GD
McElroy
Eric B
EB
McGlynn
Molly A
MA
Paradis
Timothy J
TJ
Poss
Christopher S
CS
Roache
James H
JH
Shavnya
Andrei
A
Shepard
Richard M
RM
Trevena
Kristen A
KA
Tylaska
Laurie A
LA
D000818:Animals; D004285:Dogs; D000882:Haplorhini; D006801:Humans; D008862:Microsomes, Liver / Q000378:metabolism; D010879:Piperazines / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism*; D051381:Rats; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
C515300:CCR1 protein, human; C515302:Ccr1 protein, rat; D010879:Piperazines; D054389:Receptors, CCR1; D019707:Receptors, Chemokine